In recent years, the popularity of fly agaric «microdosing» has increased, which involves their systematic use in small doses (usually several grams) in order to provide a "therapeutic effect without harm to the body." The market offers capsules, dried caps of red fly agaric (Amanita muscaria) and pantherine fly agaric (Amanita pantherina), which until recently were actively sold by individual...
ABSTRACT Joshua Falcon's comprehensive synthesis, “Anthropology of Psychedelics,” significantly addresses gaps in psychedelic anthropology, particularly urban practices in the Global North and decolonial considerations. This commentary expands upon Falcon's work by incorporating recent clinical studies and sociocultural analyses that reinforce his proposed directions. Empirical evidence from...
Microdosing psychedelics, including lysergic acid diethylamide (LSD), has gained attention for its potential benefits in several psychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD). However, LSD's efficacy in reducing ADHD symptoms remains unknown. To determine the safety and efficacy of repeated low doses of LSD in reducing ADHD symptoms compared with placebo. This...
Psilocybin, a serotonergic psychedelic, may have therapeutic benefits for Substance Use Disorders (SUDs), but its overall efficacy and safety remain uncertain. This systematic review assessed the safety and efficacy of psilocybin for SUDs through a systematic database search conducted via OVID on May 22, 2024, and summarized 26 ongoing clinical trials registered on clinicaltrials.gov. Among 16...
Abstract Ketamine has transformed depression treatment by providing therapeutic relief within a single day, unlike monoaminergic antidepressants that require weeks to take effect. Here, we conducted whole-brain screening in mice to compare drug-evoked c-fos expression—acting as a marker of brain activity leading to protein synthesis-dependent forms of plasticity—following treatment with...
Psychedelic drugs, particularly taking small amounts of psychedelics in a cyclical pattern over days (so-called microdosing), have garnered growing scientific and public interest, but representative data on different dosage levels is scarce. To better understand this trend, we surveyed a nationwide sample of 11,299 adults in Germany. The survey assessed lifetime and past six-month psychedelic...
Introdução: A utilização dos psicodélicos como alternativa no tratamento de transtornos mentais é debatida desde a sua descoberta, sendo que estudos a respeito dessas substâncias sofreram uma série de entraves jurídicos após a popularização do seu uso recreativo. Entretanto, a atenção sobre essa classe farmacológica ressurgiu, especialmente à utilização no esquema de “microdoses”, definido como...
Treating amotivated states remains difficult. Classical psychedelic drugs (5-HT2A receptor agonists) such as LSD and psilocybin have shown therapeutic potential in treating such symptoms, but their development has been hindered by their undesirable hallucinogenic effects. There is increasing evidence that administration of psychedelics at dose levels too low to evoke a hallucinogenic effect...
Introduction: High-dose psilocybin has shown potential in treating various psychiatric disorders, but its perceptual and cognitive effects, along with the risk of adverse events, highlight the need for alternative treatment approaches. One such approach is the use of low-dose psilocybin, which does not significantly alter cognition or perception. While low-dose psilocybin has garnered growing...
Motives are a highly influential force in substance use and vary depending on the substance or dose being used. Little research has compared motives across different doses of psilocybin. Psilocybin is often ingested in microdoses (0.1–0.4 g) or macrodoses (1 g+), each producing unique perceptual and mood effects. The current study examined whether motives for microdose and macrodose psilocybin...